 |
| |
| |
At the base of the activities of the Vialli and Mauro Foundation for Research and Sport is the desire to operate concretely and to always be transparent. For this reason, in this section we intend to give you the possibility of knowing in detail and seeing how the dispersed funds will be used.
The objectives that we submit are: |
|
|
| |
 |
| |
Today, the mammogram is still, despite its limits, the technology of excellence for the discovery of small dimension mammary carcinoma. This is not only in relation to the simplicity of execution and contained costs, but also due to the recent transformation of the same analogue technology (traditional) into digital technology. For additional information, click here.
The Hospital of Candiolo
|
 |
|
| |
|
| Collective Funds: 286.383,00 € |
Overall cost: 286.383,00 € |
|
|
| |
|
|
|
| |
 |
| |
Research conducted personally by Dr. Letizia Mazzini (Neurological Clinic - Amedeo Avogadro University of Piedmont Orientale - Novara), that will have the possibility of following the course of patients afflicted with Amyotrophic Lateral Sclerosis and surgical interventions.
To develop the research guidelines provided in the study, it requires a completely dedicated researcher available at the University of Novara for a period of at least five years. The forecasted gross cost is 30,000.00 Euro per year for a total of 150,000.00 Euro. For additional information, click here |
|
Con il contributo di
 |
|
| Go to the news: CLINICAL STUDY IN PHASE 1 "CLINICAL APPLICATION OF AUTOLOGOUS MESENCHYMAL STEM CELLS" |
Target achieved The first scientific study regarding the Stem Cell research in Amyotrophic Lateral Sclerosis as been published
 |
"Stem cell treatment in
Amyotrophic Lateral Sclerosis"
Journal of the
Neurological Sciences (2007)
Link | Complete Article (Pdf, 382 Kb) | Read the news |
| |
|
 |
Obiettivo 2005-2006 - STUDIO CLINICO IN FASE 1 "APPLICAZIONE CLINICA DELLE CELLULE STAMINALI MESENCHIMALI AUTOLOGHE NELLA SCLEROSI LATERALE AMIOTROFICA"
Responsabile: dott Letizia Mazzini, Clinica Neurologica, Università del Piemonte Orientale, Novara (giugno 2008)
Link | Articolo Completo (Pdf, 16 Kb) |
| |
|
 |
Richiesta del progetto:
Obiettivo 2005-2006 STUDIO CLINICO IN FASE 1 "APPLICAZIONE CLINICA DELLE CELLULE STAMINALI MESENCHIMALI AUTOLOGHE NELLA SCLEROSI LATERALE AMIOTROFICA"
Responsabile: dott Letizia Mazzini, Clinica Neurologica, Università del Piemonte Orientale, Novara
Link | Vedi richiesta progetto |
| |
|
 |
Lettera di proroga della borsa di studio:
OGGETTO: Borsa di studio per progetto: STUDIO CLINICO IN FASE 1 "Applicazione clinica delle cellule staminali mesenchinali autologhe nella sclerosi laterale amiotrofica"
Link | Vedi la Lettera di proroga della borsa di studio |
|
| |
|
| Collective Funds: 50.000,00 € |
Overall cost: 68.000,00 € |
|
|
| |
|
|
|
|
| |
 |
| |
| Studies are in progress in the Stem Cell Transplant Laboratory of the Regina Margherita Hospital of Turin regarding the mesenchymal stem cells (MSC). The MSC are drawn from a healthy individual and cultivated in a laboratory to be able to transplant them in diseased subjects for therapeutic purposes. In this case, the human MSC are isolated and expanded, originating from the medulla ossium (bone marrow) and driven to differentiation in a neutral sense in vitro. |
 |
The differentiation of the MSC into neutral cells is studied by means of biological cellular, molecular and electrophysiological techniques. In particular, the MSC placed in culture with diverse agents of differentiation including ß-mercaptoethanol; dimethyl sulfoxide + ß-hydroxyanisole; trans-retinoic acid and Neural Progenitor Maintenance Medium are able to modify their morphology (assuming a semi-neural aspect), express neural markers (including Nestin, Neuron-Specific Enolase; the antigen Neuronal Nuclear, the type 2 Microtubule-associated Protein and the Glial Fribrillary Acidic Protein) and present currents associated to the K+ channels raised by means of electrophysiological techniques. These cells (MSC) are able to excrete substances which favour the growth of the neurons and their prolongation.
Moreover, to study the capacity of the MSC to slow the progression of the neuronal damage and the eventual regeneration of the damaged nerve tissue, in the Human Anatomy and Legal Medicine laboratory of the University of Studies in Turin, directed by Prof. Alessandro Vercelli, in vivo studies are in progress on an experimental model of amyotrophic lateral sclerosis in mice. As a model, SOD-1 mice are used, that is a carrier of the mutated gene of the superoxide-dimutase of type 1. Such mutation provokes in mice a clinical picture similar to that of the patients afflicted with the familial form of Amyotrophic Lateral Sclerosis, a disease characterised by the progressive degeneration of motoneurons with consequent atrophy and muscular paralysis. The human MSC are marked with a nuclear colorant (Bisbenzimide) and inoculated in the spinal cord level. The results obtained to date demonstrate how the MSC inoculated at a spinal cord level of these mice are able to root, migrate, and survive in the long term and reduce the reactive astrogliosis, slowing the progression of the pathology. Such results reflect from a functional point of view in the improvement in the behavioural tests, therefore, in the motor functions in the transplanted mice. It is our intention to use the MSC to administer substances that prevent the neuronal death in the spinal cord location.
To continue such studies, the use of new instruments are deemed necessary including a laminar flow hood for the manipulation of cellular cultures with UV lamp and empty tap and a large capacity centrifuge counter ventilated for the isolation and expansion of the mesenchymal stem cells.
Project Manager:
Dr. Franca Fagioli
STEM CELL TRANSPLANT AND CELLULAR THERAPY CENTRE
University of Studies of Turin
Regina Margherita Hospital
Piazza Polonia, 94 – Turin
Go to the news: CLINICAL STUDY IN PHASE 1 "CLINICAL APPLICATION OF AUTOLOGOUS MESENCHYMAL STEM CELLS FOR AMYOTROPHIC LATERAL SCLEROSIS"
24/08/06 - The confirmation of the acquisition of the following machines from the Thermo Electron Corporation:
Price reserved for us 11,266.00 Euro
code 82024100: Maxi Safe 2010 1.8/ with divided work station
code 52270240: UV Lamp with timer
Price reserved for us 4,785.00 Euro
code 11177560: Centrifuge C4i
code 11175338: M4 oscillating rotor
code 11174218: Set 4 vial racks
code 11174529: Set 4 adaptors
Price reserved for us 5,258.40 Euro
code 19371: Incubator + 8 door Kit
Total order in Euro 21,309.40 + vat 20%= Euro 25,571.28.
23/03/2008 Macchinari istallati e collaudati presso il Centro Trapianti
di Piazza Polonia 94 – Torino (Foto 1 - Foto 2 - Foto 3)
10/01/2007: pagato acconto macchinari € 6.392,82
(fatt. n. d/2 06 00 2508 Thermo Fisher Scientific)
15/07/2008: pagato saldo macchinari € 19.178,46
(fatt. n. d/2 06 00 2508 Thermo Fisher Scientific) |
|
| |
|
| Collective Funds: 25.571,28 € |
Overall cost: 25.571,28 € |
|
|
| |
|
|
|
| |
 |
| |
| A recent epidemiologic study on professional Italian football players engaged in series A and B between 1970 and 2001 showed how the frequency of ALS is significantly higher (approximately 6.5 times) and the age of onset is net inferior (on average 43 years) with respect to the occurrence in the general Italian population. (Brain Article). The origin of such increase and precocity is unknown. |
 |
|
| |
It is possible to hypothesise, beyond the intense physical activity typical of an agonistic sport, that the increase in frequency is correlated to the use of substances assumed for the improvement in athletic performance and/or the use of pharmaceuticals for a prolonged period or in greater quantities with respect to the indicated therapeutic use. It is also assumable that there is a correlation with the specific traumas related to the game of football (for example, the headshot) or the prolonged exposure to toxins such as fertilisers and herbicides used on the football fields.
The fact that despite all of the football players examined being exposed to the same or similar environmental risk factors and only some of them contracted ALS indicates that the genetic characteristics that predispose some individuals to develop the disease probably exist. Therefore, to deepen the awareness regarding possible environmental factors and to identify the predisposed genes may provide very useful elements to identifying the origin of the disease in the 4000 Italian patients that are not professional football players.
The principal objectives are therefore, those of researching the bio-molecular characteristics that can define the increase in risk of developing ALS in professional football players and by means of these characteristics, identifying possible diagnostic indicators of the disease and possible targets for the development of new strategic therapies.
The study is pre-established to 1) investigate the clinical characteristics of Italian football players afflicted with ALS by retrospective and prospective analysis of all of the cases noted from 1970; 2) identify eventual genetic polymorphisms (polymorphisms) as possible risk factors for the development of the disease in professional football players; 3) develop cellular models obtained from peripheral tissues (e.g. primary lymphocyte and fibroblast cultures) (cellular cultures) with which it is possible to investigate mechanisms involved in the process of neurodegeneration; 4) identify by means of proteome analysis (proteome analysis) new biochemical indicators that are characteristic of the disease.
This study was created by the consolidated collaboration between Dr. Gabriele Mora of the Salvatore Maugeri Foundation in Pavia and Prof. Adriano Chiò of the Department of Neuroscience in Turin who were the authors of the survey on ALS in football players, along with the basic scientific contributions by Dr. Caterina Bendotti of the Department of Neuroscience at the "Mario Negri" Institute who has worked in this area for numerous years.
Allegati Borsa di Studio (Dipartimento di Neuroscienze dell'Istituto "Mario Negri"):
- Bando di Concorso per 1 borsa di studio per laureati in discipline biomediche;
- Lettera Dott.essa Silvia Pozzi;
- Lettera a Fondazione Vialli e Mauro.
Allegati Borsa di Studio (Dipartimento di Neuroscienze di Torino):
- Bando per assegnamento della Borsa di Studio;
- CV (Dott.essa Maura Brunetti);
- Verbale della commissione;
- Richiesta di erogazione fondi per Borsa di Studio (Prof. Filippo Bogetto).
The overall cost of this study amounts to 220,000 Euro and includes 3 biennial scholarships, the necessary reactants for conducting the experiment and the acquisition of an instrument (Bio-Plex System, Bio-Rad). (Bioplex)
Vedi: Bio-Plex Suspension Array System - Scheda tecnica cod. n. 171000201
Scheda Tecnica Bioplex
For additional information on ALS, click here
Request:
Human Resources
1 biennial biology scholarship at the Mario Negri Institute (cost € 30,000)
1 biennial biology scholarship at the Maugeri Foundation (cost € 40,000)
1 biennial biology scholarship in the Department of Neuroscience in Turin
(cost € 40,000)
Material and equipment:
Bio-plex System (Bio-rad): equipment for the simultaneous determination of diverse molecules of interest (cytokines, phosphoproteins, cellular death factors).
Approximate cost € 72,000.
Read the Press Release here |
|
Consumption material (antibodies, enzymes, immunohistochemistry kits, culture mediums, genetic primers and isolation kits, etc.) Approximate cost € 50,000.
07/05/ 2007: Acquistato Bioplex euro 72.000
(Bio-Rad Laboratories s.r.l, fattura n° S01/20710589 del 26/3/2007);
18/09/2007: Erogato finanziamento euro 30.000 per borsa di Studio presso Istituto Mario Negri di Milano;
23/01/2008: Pagata prima richiesta di materiale di consumo, € 9.456,00
(Link: visualizza la fattura);
26/03/2008: Pagata seconda richiesta di materiale di consumo, € 20.000
(vedi allegato: Fondazione Vialli e Mauro contributo spese)
15/07/2008: Erogato finanziamento euro 40.000 per borsa di Studio presso Dipartimento di Neuroscienze Università degli Studi di Torino
Project Managers:
This project is created by the consolidated collaboration among 3 researchers that have operated in the clinical and research areas of ALS for many years.
|
|
|
| |
| |
QUALI RISULTATI SONO STATI RAGGIUNTI:
Dicembre 2007: Relazione sull’attività svolta nei primi sei mesi dall’acquisizione dell’apparecchiatura BIOPLEX donata per lo studio della SLA (pdf) |
| |
Marzo 2008: Rapporto d’attività dei primi 6 mesi presso l’Istituto Mario Negri
(Settembre 2007- Marzo 2008) |
| |
| Settembre 2008: Report sull'attività svolta dal 2/05/08 al 31/07/08 presso il laboratorio di Genetica Molecolare dell' ASO O.I.R.M. S.Anna (Torino) - (pdf) |
| |
| Settembre 2008: Rapporto d'attività del periodo MARZO 2008 – SETTEMBRE 2008 presso l'Istituto Mario Negri ( Scarica PDF - Scarica DOC ) |
| |
|
| Project duration: 24 months |
|
| Collective Funds: 232.000,00
€ |
Overall cost: 232.000,00 € |
|
|
| |
|
|
|
| |
 |
| |
The High Technological Content Communicator
"If you would like to know how it feels when it is impossible to communicate, go to a meeting and pretend that you cannot talk. Use your hands but not paper and pencil because these are not used by persons with grave physical disabilities that are unable to verbally express themselves. You will be surrounded by persons that speak in front of you, behind you, around you, under you, across you and even for you, but never with you. You will be ignored to the point that you will feel as though you are an element of decor."
Mario Melazzini, afflicted with ALS
|
 |
|
|
Systems of increased alternative communication have been used for years to allow for communication by patients during even in the most advanced stages of ALS in which only small residual movements are possible, sometimes only in one bodily area.
Such systems, based on a hardware driver for word processing are often installed on a portable computer that is equipped with specific software, and use, in a majority of cases, a method of letter scanning. In this case, they are commanded by an individual button which is activated by the residual bodily movement for as long as it remains. In the more advanced phases of the disease, often only the ocular movement remains to connect the patient with the surrounding world, meanwhile he is always and nonetheless conscious and needs to express himself, to ask clarifying questions regarding his pathology, to share in the choices with his doctors regarding his care, to express his emotions to family and friends and to participate in social activities by exchanging opinions and thoughts with others. |
Today, in these extreme cases, technology can do a lot to allow the patient to remain connected with the surrounding environment.
For such purpose, an ocular controlled operational system was created that due to a telecamera which is connected to a computer along with specific software, allows for writing, navigating the internet, reading, writing and sending e-mails, controlling lights and domestic appliances as well as many other operations.
These systems of high technological content use a high resolution telecamera that is able to discern the movement of the pupils in real-time and by means of the software with which they are equipped, are able to identify with extraordinary precision on which area of the screen is being focused. This system coupled with a virtual keyboard is being used with optimal results. Due to this technology, it is only necessary to be able to focus on the letters which are present on the screen in order to be able to write. The cost of said system currently exceeds 20,000-24,000 Euro, even though more economical systems that are less precise and reliable and costing approximately 7-8,000 Euro have recently appeared on the marketplace.
The technological characteristics are as follows:
An Eye-tracking system of a remote and binocular type with a tolerance capacity for head movements, a rapid automatic calibration (< 1.5 minutes) and learnable data and procedures of auto-calibration during use. Said system is equipped with a software suite for communication, the ability to allow for sending/receiving of electronic mail (including the management of eventual jpg file attachments), internet navigation, the implementation of VoIP telephone calls by the integration of a TTS system (Text-To-Speech) and a video keypad, the management of an archive of images and text through a facilitated file manager, an agenda including visuals (therefore equipped with photos) for saving and managing contacts, a text facilitated reader (txt format); all applications are equipped with an user interface that is simple and intuitive and only and exclusively controllable by the eyes (ocular movement). Moreover, the system must be equipped with a series of virtual keyboards with ocular control (i.e., interfaces with eye-tracker), an integrated vocal synthesiser and an electronic post account and telephone that are all included and personalised. In consideration of the distinctive physical condition of the patient, and for an increased timeliness in the personalization of and adjustments to the system, a procedure of remote technical intervention that is able to modify all of the operating parameters of the system itself must also be included.
For additional information's "Eye - Trackers for the Research" (pdf)
The "VIALLI AND MAURO" Foundation and the AISLA ONLUS Project
Currently, the AISLA Onlus, by enormous financial sacrifice, has already distributed by complimentary use agreement, 13 “I Able My Tobii” communicators to the patients/members that had an urgent need of them.
Furthermore, based on the efforts instituted by the AISLA in collaboration with the Minister of Public Health, the State-Regional Conference recently approved the appropriation of 10 million Euro to be divided among the various Regions of Italy to be used to acquire additional high technological content communicators to be allocated to those afflicted with ALS.
"Freedom of Speech: An Announcement by the Minster
of Public Health
Livia Turco" (pdf)
It is the intention of the AISLA Onlus to acquire an additional 10 communicators to provide to patients by complimentary use agreement and the Vialli and Mauro Foundation Onlus will contribute to the expenses for 5 devices.
See the Aisla My Tobii's Official Request (pdf)
Attached is an excerpt of the My Tobii® purchase contract as agreed between AISLA Onlus and SR LABS S.r.l in June of 2007.
See the Supplier's Contract (pdf)
24/10/2007 1st Down Payment of Euro 35,554.48 paid by the Foundation.
Download pdf
28/11/07 2nd Down Payment of Euro 35.554,48 paid by the Foundation.
Download pdf
02/10/08 Pagato saldo dalla Fondazione, euro 17.777,24
Scarica l'allegato (jpg) |
| |
|
| Funds Collected: 88.886,20 € |
Total Cost: 88.886,20 € |
|
|
| |
|
|
|
| |
 |
| |
L'elettromiografo è un'apparecchiatura in grado di rilevare, memorizzare ed elaborare i segnali elettrici connessi con l'attività muscolare di qualsiasi tipo e zona del corpo umano.
Grazie a questo strumento è possibile, per i malati affetti da patologie neuromuscolari, in particolare per la Sclerosi Laterale Amiotrofica, rilevare i segni di sofferenza del II motoneurone tramite lo studio del sistema nervoso periferico e la registrazione dell'attività elettrica muscolare, permettendo, al neurologo clinico, di aggiungere un tassello importante per arrivare alla diagnosi di certezza della malattia.
|
|
|
In particolare l'elettromiografia è utile per:
• Localizzare il disturbo;
• Identificare il processo patologico sottostante;
• Caratterizzare il deficit;
• Valutare la gravità del deficit;
• Monitorizzare il decorso della malattia;
• Valutare l'efficacia delle terapie eventuali adottate.
Il costo completo di questo strumento sarà di circa 50.000 Euro, ed il suo utilizzo sarà previsto presso il Centro Clinico Nemo di Milano, presso l'Azienda Ospedaliera Niguarda. Centro nato e voluto grazie alla collaborazione, tenacia tra AISLA e UILDM, e creato per la diagnosi e la cura delle malattie neuromuscolari. E' il primo modello concreto di sussidiarietà, con l'obiettivo reale di garantire al malato la presa in carico globale. |
 |
| |
|
|
|
| Collective Funds: 50.000,00 € |
Total Cost: 50.000,00 € |
|
|
|
| |
| |
|
| |
| FONDI DA DESTINARE "OBJECTIVE No. 7": 174.527,10 € |
| |
|
|
|
| |
| |
|
|
|
|
 |
|
|
English 
